{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T10:42:38Z","timestamp":1792579358142,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100015303","name":"Otsuka Pharmaceutical Development and Commercialization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015303","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"DOI":"10.1007\/s40120-026-01028-5","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T10:10:36Z","timestamp":1792577436000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Outcomes Among Patients with Major Depressive Disorder with Hyperarousal Symptoms Taking Brexpiprazole as Augmentation to Antidepressant Treatment in a United States Real-World Setting"],"prefix":"10.1007","author":[{"given":"Stevan Geoffrey","family":"Severtson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dusica","family":"Hadzi Boskovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra F.","family":"Eisenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferhat","family":"Ardic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Abdrabboh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl D.","family":"Marci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"issue":"3","key":"1028_CR1","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1037\/a0034028","volume":"122","author":"BN Cuthbert","year":"2013","unstructured":"Cuthbert BN, Kozak MJ. Constructing constructs for psychopathology: the NIMH research domain criteria. J Abnorm Psychol. 2013;122(3):928\u201337. https:\/\/doi.org\/10.1037\/a0034028.","journal-title":"J Abnorm Psychol"},{"issue":"2","key":"1028_CR2","doi-asserted-by":"publisher","DOI":"10.2196\/11167","volume":"11","author":"E Chiauzzi","year":"2019","unstructured":"Chiauzzi E, Drahos J, Sarkey S, Curran C, Wang V, Tomori D. Patient perspective of cognitive symptoms in major depressive disorder: retrospective database and prospective survey analyses. J Particip Med. 2019;11(2):e11167. https:\/\/doi.org\/10.2196\/11167.","journal-title":"J Particip Med"},{"key":"1028_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jad.2013.09.012","volume":"152-154","author":"MH Trivedi","year":"2014","unstructured":"Trivedi MH, Greer TL. Cognitive dysfunction in unipolar depression: implications for treatment. J Affect Disord. 2014;152\u2013154:19\u201327. https:\/\/doi.org\/10.1016\/j.jad.2013.09.012.","journal-title":"J Affect Disord"},{"issue":"3","key":"1028_CR4","doi-asserted-by":"publisher","first-page":"329","DOI":"10.31887\/DCNS.2008.10.3\/dnutt","volume":"10","author":"D Nutt","year":"2008","unstructured":"Nutt D, Wilson S, Paterson L. Sleep disorders as core symptoms of depression. Dialogues Clin Neurosci. 2008;10(3):329\u201336. https:\/\/doi.org\/10.31887\/DCNS.2008.10.3\/dnutt.","journal-title":"Dialogues Clin Neurosci"},{"key":"1028_CR5","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.jpsychires.2024.11.074","volume":"181","author":"M Rizk","year":"2025","unstructured":"Rizk M, Tebeka S, Dubertret C, Le Strat Y. Prevalence, correlates and comorbidity of irritability in adults with major depressive episode in the U.S. population (2012\u20132013). J Psychiatr Res. 2025;181:517\u201322. https:\/\/doi.org\/10.1016\/j.jpsychires.2024.11.074.","journal-title":"J Psychiatr Res"},{"issue":"4","key":"1028_CR6","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/j.1600-0447.2008.01298.x","volume":"119","author":"RH Perlis","year":"2009","unstructured":"Perlis RH, Fava M, Trivedi MH, et al. Irritability is associated with anxiety and greater severity, but not bipolar spectrum features, in major depressive disorder. Acta Psychiatr Scand. 2009;119(4):282\u20139. https:\/\/doi.org\/10.1111\/j.1600-0447.2008.01298.x.","journal-title":"Acta Psychiatr Scand"},{"issue":"8","key":"1028_CR7","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/mp.2009.20","volume":"15","author":"M Fava","year":"2010","unstructured":"Fava M, Hwang I, Rush AJ, Sampson N, Walters EE, Kessler RC. The importance of irritability as a symptom of major depressive disorder: results from the National Comorbidity Survey Replication. Mol Psychiatry. 2010;15(8):856\u201367. https:\/\/doi.org\/10.1038\/mp.2009.20.","journal-title":"Mol Psychiatry"},{"issue":"2","key":"1028_CR8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.4088\/JCP.v66n0202","volume":"66","author":"RH Perlis","year":"2005","unstructured":"Perlis RH, Fraguas R, Fava M, et al. Prevalence and clinical correlates of irritability in major depressive disorder: a preliminary report from the Sequenced Treatment Alternatives to Relieve Depression study. J Clin Psychiatry. 2005;66(2):159\u201366.","journal-title":"J Clin Psychiatry"},{"key":"1028_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.neubiorev.2012.10.008","volume":"44","author":"U Hegerl","year":"2014","unstructured":"Hegerl U, Hensch T. The vigilance regulation model of affective disorders and ADHD. Neurosci Biobehav Rev. 2014;44:45\u201357. https:\/\/doi.org\/10.1016\/j.neubiorev.2012.10.008.","journal-title":"Neurosci Biobehav Rev"},{"issue":"8","key":"1028_CR10","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1080\/13607863.2021.1950617","volume":"26","author":"ASS Siqueira","year":"2022","unstructured":"Siqueira ASS, Biella MM, Borges MK, et al. Decision-making executive function profile and performance in older adults with major depression: a case-control study. Aging Ment Health. 2022;26(8):1551\u20137. https:\/\/doi.org\/10.1080\/13607863.2021.1950617.","journal-title":"Aging Ment Health"},{"issue":"4","key":"1028_CR11","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.plunaro2417ah","volume":"85","author":"R Jain","year":"2024","unstructured":"Jain R, Chepke C, Davis LL, McIntyre RS, Raskind MA. Dysregulation of noradrenergic activity: its role in conceptualizing and treating major depressive disorder, schizophrenia, agitation in Alzheimer\u2019s disease, and posttraumatic stress disorder. J Clin Psychiatry. 2024;85(4):plunaro2417ah. https:\/\/doi.org\/10.4088\/JCP.plunaro2417ah.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"1028_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/pcn.12126","volume":"68","author":"K Yamamoto","year":"2014","unstructured":"Yamamoto K, Shinba T, Yoshii M. Psychiatric symptoms of noradrenergic dysfunction: a pathophysiological view. Psychiatry Clin Neurosci. 2014;68(1):1\u201320. https:\/\/doi.org\/10.1111\/pcn.12126.","journal-title":"Psychiatry Clin Neurosci"},{"key":"1028_CR13","volume-title":"The neurobiological basis of suicide","author":"MJ Chandley","year":"2012","unstructured":"Chandley MJ, Ordway GA. Chapter 3. Noradrenergic dysfunction in depression and suicide. In: Dwivedi Y, editor. The neurobiological basis of suicide. Boca Raton: CRC Press\/Taylor & Francis; 2012."},{"issue":"3","key":"1028_CR14","doi-asserted-by":"publisher","first-page":"H337","DOI":"10.1152\/ajpheart.00590.2021","volume":"322","author":"IM Greenlund","year":"2022","unstructured":"Greenlund IM, Carter JR. Sympathetic neural responses to sleep disorders and insufficiencies. Am J Physiol Heart Circ Physiol. 2022;322(3):H337\u201349. https:\/\/doi.org\/10.1152\/ajpheart.00590.2021.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"3","key":"1028_CR15","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1124\/jpet.114.213793","volume":"350","author":"K Maeda","year":"2014","unstructured":"Maeda K, Sugino H, Akazawa H, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin\u2013dopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3):589\u2013604. https:\/\/doi.org\/10.1124\/jpet.114.213793.","journal-title":"J Pharmacol Exp Ther"},{"key":"1028_CR16","unstructured":"Otsuka Pharmaceutical Co. Ltd. Rexulti\u00ae (brexpiprazole) tablets, for oral use. Prescribing information [United States]. 2025 [cited 2025 June 13]. https:\/\/www.otsuka-us.com\/media\/static\/Rexulti-PI.pdf."},{"issue":"9","key":"1028_CR17","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.4088\/JCP.14m09688","volume":"76","author":"ME Thase","year":"2015","unstructured":"Thase ME, Youakim JM, Skuban A, et al. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a Phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry. 2015;76(9):1224\u201331. https:\/\/doi.org\/10.4088\/JCP.14m09688.","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"1028_CR18","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.4088\/JCP.14m09689","volume":"76","author":"ME Thase","year":"2015","unstructured":"Thase ME, Youakim JM, Skuban A, et al. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a Phase 3, randomized, double-blind study. J Clin Psychiatry. 2015;76(9):1232\u201340. https:\/\/doi.org\/10.4088\/JCP.14m09689.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"1028_CR19","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.17m12058","volume":"79","author":"M Hobart","year":"2018","unstructured":"Hobart M, Skuban A, Zhang P, et al. A randomized, placebo-controlled study of the efficacy and safety of fixed-dose brexpiprazole 2 mg\/d as adjunctive treatment of adults with major depressive disorder. J Clin Psychiatry. 2018;79(4):17m12058. https:\/\/doi.org\/10.4088\/JCP.17m12058.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"1028_CR20","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1080\/03007995.2018.1430220","volume":"34","author":"M Hobart","year":"2018","unstructured":"Hobart M, Skuban A, Zhang P, et al. Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study. Curr Med Res Opin. 2018;34(4):633\u201342. https:\/\/doi.org\/10.1080\/03007995.2018.1430220.","journal-title":"Curr Med Res Opin"},{"issue":"15","key":"1028_CR21","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1080\/14656566.2019.1638913","volume":"20","author":"ME Thase","year":"2019","unstructured":"Thase ME, Zhang P, Weiss C, Meehan SR, Hobart M. Efficacy and safety of brexpiprazole as adjunctive treatment in major depressive disorder: overview of four short-term studies. Expert Opin Pharmacother. 2019;20(15):1907\u201316. https:\/\/doi.org\/10.1080\/14656566.2019.1638913.","journal-title":"Expert Opin Pharmacother"},{"key":"1028_CR22","doi-asserted-by":"publisher","unstructured":"Hadzi Boskovic D, Huang D, Severtson SG, et al. Clinical outcomes among patients taking brexpiprazole as augmentation with antidepressant treatment for major depressive disorder in a United States real-world dataset. Neurol Ther. 2026. https:\/\/doi.org\/10.1007\/s40120-026-01027-6.","DOI":"10.1007\/s40120-026-01027-6"},{"key":"1028_CR23","unstructured":"Severtson SG, Hadzi Boskovic D, Marci C, Eisenberg DF, Abdrabboh A, Ardic F. Long-term real-world outcomes among patients with major depressive disorder with anxiety-related diagnosis taking brexpiprazole as augmentation with antidepressant. Neurol Ther. 2026."},{"key":"1028_CR24","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jad.2025.01.152","volume":"376","author":"P Alves","year":"2025","unstructured":"Alves P, Marci CD, Cohen-Stavi CJ, Whelan KM, Boussios C. A machine learning model using clinical notes to estimate PHQ-9 symptom severity scores in depressed patients. J Affect Disord. 2025;376:216\u201324. https:\/\/doi.org\/10.1016\/j.jad.2025.01.152.","journal-title":"J Affect Disord"},{"key":"1028_CR25","volume-title":"Artificial intelligence-based estimation of the CGI-I to address gaps in real-world data and increase study sample size","author":"MB Leavy","year":"2025","unstructured":"Leavy MB, Bryant Z, Marci C, Boussios C. Artificial intelligence-based estimation of the CGI-I to address gaps in real-world data and increase study sample size. Washington DC: International Society for Pharmaceutical Engineering Annual Meeting; 2025."},{"issue":"2","key":"1028_CR26","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/bf02295996","volume":"12","author":"Q McNemar","year":"1947","unstructured":"McNemar Q. Note on the sampling error of the difference between correlated proportions or percentages. Psychometrika. 1947;12(2):153\u20137. https:\/\/doi.org\/10.1007\/bf02295996.","journal-title":"Psychometrika"},{"issue":"9","key":"1028_CR27","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","volume":"16","author":"K Kroenke","year":"2001","unstructured":"Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606\u201313. https:\/\/doi.org\/10.1046\/j.1525-1497.2001.016009606.x.","journal-title":"J Gen Intern Med"},{"issue":"10","key":"1028_CR28","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1017\/S0033291720003700","volume":"52","author":"D Kounali","year":"2022","unstructured":"Kounali D, Button KS, Lewis G, et al. How much change is enough? Evidence from a longitudinal study on depression in UK primary care. Psychol Med. 2022;52(10):1875\u201382. https:\/\/doi.org\/10.1017\/S0033291720003700.","journal-title":"Psychol Med"},{"key":"1028_CR29","doi-asserted-by":"publisher","first-page":"1618176","DOI":"10.3389\/fpsyt.2025.1618176","volume":"16","author":"F Ardic","year":"2025","unstructured":"Ardic F, Zhang Z, Hogan M. Effects of adjunctive brexpiprazole in patients with major depressive disorder and sleep disturbance: a post hoc analysis of three randomized trials. Front Psychiatry. 2025;16:1618176. https:\/\/doi.org\/10.3389\/fpsyt.2025.1618176.","journal-title":"Front Psychiatry"},{"issue":"5","key":"1028_CR30","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.15m01914","volume":"18","author":"AD Krystal","year":"2016","unstructured":"Krystal AD, Mittoux A, Meisels P, Baker RA. Effects of adjunctive brexpiprazole on sleep disturbances in patients with major depressive disorder: an open-label, flexible-dose, exploratory study. Prim Care Companion CNS Disord. 2016;18(5):10.4088\/PCC.15m01914. https:\/\/doi.org\/10.4088\/PCC.15m01914.","journal-title":"Prim Care Companion CNS Disord"},{"issue":"12","key":"1028_CR31","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.4088\/JCP.15m10470","volume":"77","author":"M Fava","year":"2016","unstructured":"Fava M, M\u00e9nard F, Davidsen CK, Baker RA. Adjunctive brexpiprazole in patients with major depressive disorder and irritability: an exploratory study. J Clin Psychiatry. 2016;77(12):1695\u2013701. https:\/\/doi.org\/10.4088\/JCP.15m10470.","journal-title":"J Clin Psychiatry"},{"key":"1028_CR32","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jpsychires.2023.04.012","volume":"162","author":"RS McIntyre","year":"2023","unstructured":"McIntyre RS, Therrien F, Ismail Z, et al. Effects of adjunctive brexpiprazole on patient life engagement in major depressive disorder: post hoc analysis of Inventory of Depressive Symptomatology Self-Report data. J Psychiatr Res. 2023;162:71\u20138. https:\/\/doi.org\/10.1016\/j.jpsychires.2023.04.012.","journal-title":"J Psychiatr Res"},{"key":"1028_CR33","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jad.2017.09.054","volume":"227","author":"JC Nelson","year":"2018","unstructured":"Nelson JC, Weiller E, Zhang P, Weiss C, Hobart M. Efficacy of adjunctive brexpiprazole on the core symptoms of major depressive disorder: a post hoc analysis of two pooled clinical studies. J Affect Disord. 2018;227:103\u20138. https:\/\/doi.org\/10.1016\/j.jad.2017.09.054.","journal-title":"J Affect Disord"},{"key":"1028_CR34","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425787","volume-title":"Diagnostic and statistical manual of mental disorders, fifth edition, text revision","author":"American Psychiatric Association","year":"2022","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fifth edition, text revision. Washington, DC: American Psychiatric Association; 2022."},{"key":"1028_CR35","doi-asserted-by":"publisher","unstructured":"Awasthi S, Hadzi Boskovic D, Bhattacharjee S, Kapadia S. Early adjunctive brexpiprazole initiation for major depressive disorder: impact on healthcare resource utilization and cost\u2014a US real-world analysis. J Manag Care Spec Pharm. 2024;30(4-a Suppl):S57. https:\/\/doi.org\/10.18553\/jmcp.2024.30.4-a.s1.","DOI":"10.18553\/jmcp.2024.30.4-a.s1"},{"key":"1028_CR36","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2147\/ndt.S91311","volume":"12","author":"A Montoya","year":"2016","unstructured":"Montoya A, Bruins R, Katzman MA, Blier P. The noradrenergic paradox: implications in the management of depression and anxiety. Neuropsychiatr Dis Treat. 2016;12:541\u201357. https:\/\/doi.org\/10.2147\/ndt.S91311.","journal-title":"Neuropsychiatr Dis Treat"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01028-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-01028-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01028-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T10:10:38Z","timestamp":1792577438000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-01028-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":36,"alternative-id":["1028"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-01028-5","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]},"assertion":[{"value":"13 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Stevan Geoffrey Severtson was an employee of OM1, Inc. at the time of this work; Carl D. Marci is an employee of OM1, Inc.; Dusica Hadzi Boskovic and Ahmad Abdrabboh are employees of Otsuka Pharmaceutical Development & Commercialization Inc.; Debra F. Eisenberg is an employee of Lundbeck LLC; Ferhat Ardic is an employee of H. Lundbeck A\/S.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This secondary analysis used de-identified data and did not involve patient enrollment or access to personally identifiable information. The OM1 Real-World Data are HIPAA-compliant, and the study qualified for IRB exemption under 45 CFR 46.104(d)(4).","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}